CRESO PHARMA LIMITED (CPH)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CPH - CRESO PHARMA LIMITED
FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.009
26 May |
0.000 OPEN $0.01 |
0.000 HIGH $0.01 |
2,564,162 LOW $0.01 |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -2.2 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 8.7 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 1.2 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -17.3 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -377.28 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -130.99 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -130.99 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -97.43 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -130.99 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -64.62 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -17.6 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 7 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | - |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 7 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 1 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.65 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.3 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 4.01 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 14 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 13 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | - |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
0.0
No. Of Recommendations
0
CPH STOCK CHART
FNArena News on CPH
| 1 |
Flying High – Medicinal Marijuana In AustraliaJul 26 2021 - Australia |
| 2 |
ASX Companies Adopt ESG Global Reporting ToolJun 01 2021 - FYI |
| 3 |
Creso Pharma Rides Positive Cannabis TailwindsJan 13 2021 - FYI |
| 4 |
Global Regulatory Changes Mark High Point For Cannabis StocksDec 04 2020 - FYI |
| 5 |
Canopy Growth Founder Joins Creso Pharma As It Clocks $2M In Purchase Orders YTDOct 13 2020 - FYI |
